Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?

AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...

AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support

AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in treatment resistant depression. The company received supportive FDA feedback for ...

HC Wainwright bullish on AtaiBeckley (ATAI)

AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple. Analysts are ...
MarketWatch

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, ...
Fintel on MSN

Deutsche Bank initiates coverage of AtaiBeckley (ATAI) with buy recommendation

Fintel reports that on March 27, 2026, Deutsche Bank initiated coverage of AtaiBeckley (NasdaqGM:ATAI) with a Buy ...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 ...
AOL

Why Atai Life Sciences Stock Was So Lively This Week

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...
The Motley Fool

Why Atai Life Sciences Stock Stormed Higher This Week

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...
Nasdaq

atai Life Sciences Completes $63.25 Million Public Offering to Advance Mental Health Treatment Initiatives

Atai Life Sciences, a clinical-stage biopharmaceutical company focused on mental health treatments, announced the completion of a public offering on February 14, 2025, raising approximately $63.25 ...
The Motley Fool

Why Shares of atai Life Sciences Climbed 14.58% on Tuesday

Loop Capital initiated coverage of the stock with a buy rating. atai has several therapies in late-stage trials but no marketed drugs yet. The company said it has enough cash to fund operations ...
Forbes

How Atai Is Transforming The Landscape Of Mental Health Using Psychedelics (Part 1)

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...